DSS, Inc. Announces Pricing of $1.0 Million Underwritten Public Offering
Rhea-AI Summary
DSS (NYSE: DSS) priced a firm commitment underwritten public offering of 900,000 shares at $1.00 per share, with expected gross proceeds of approximately $1.0 million before fees. The underwriter has a 45-day overallotment option for an additional 135,000 shares (15%).
Aggregate proceeds are expected to be about $900,000, or $1.035 million if the over-allotment is exercised. The offering is expected to close on or about February 5, 2026. Net proceeds will be used for general corporate purposes and working capital.
Positive
- Raises approximately $1.0M in gross proceeds to fund operations
- Immediate liquidity boost for working capital and corporate needs
- Shelf registration effective under Form S-3 supports quick execution
Negative
- Issuance of 900,000 common shares may cause shareholder dilution
- Net proceeds will be reduced by underwriting fees and offering expenses
- Offering size is relatively small and may provide limited capital
News Market Reaction – DSS
In the Feb 4 session, DSS declined 32.37%, reflecting a significant negative market reaction. Argus tracked a trough of -31.6% from its starting point during tracking. Our momentum scanner triggered 18 alerts that day, indicating notable trading interest and price volatility. Trading volume was very high at 3.3x the daily average, suggesting heavy selling pressure.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Previous Offering Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Feb 03 | Equity offering launch | Neutral | +17.8% | Announced proposed common stock offering for general corporate and working capital uses. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Limited same-tag history: the prior offering-related headline on Feb 3, 2026 coincided with a 17.8% move, indicating financing news has recently triggered notable price action.
Over the past months, DSS has combined tight liquidity with financing activity. A Q3 2025 10‑Q reported higher revenue but ongoing losses and substantial doubt about going concern, alongside significant current debt. On Feb 3, 2026, DSS announced a proposed public offering for general corporate and working capital purposes under an effective registration. Today’s pricing of that offering continues this capital-raising trajectory, formalizing terms that follow yesterday’s launch announcement.
Key Terms
underwritten public offering financial
firm commitment financial
overallotment option financial
prospectus supplement regulatory
shelf registration statement regulatory
form s-3 regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
NEW YORK, Feb. 04, 2026 (GLOBE NEWSWIRE) -- DSS, Inc. (NYSE: DSS) (the “Company”), a multinational company operating across diverse industries including product packaging, biotechnology, commercial lending, and securities and investment management, today announced the pricing of a firm commitment underwritten public offering with gross proceeds to the Company expected to be approximately
The offering consists of 900,000 shares of common stock. The public offering price per share of common stock is
Aggregate gross proceeds to the Company are expected to be approximately
Aegis Capital Corp. is acting as the sole book-running manager for the offering. Sichenzia Ross Ference Carmel LLP is acting as counsel to the Company. Kaufman & Canoles, P.C. is acting as counsel to Aegis Capital Corp.
The offering is being made pursuant to an effective shelf registration statement on Form S-3 (No. 333-281974) previously filed with the U.S. Securities and Exchange Commission (SEC) on October 31, 2024, and declared effective by the SEC on November 5, 2024. A final prospectus supplement and accompanying prospectus describing the terms of the proposed offering will be filed with the SEC and will be available on the SEC’s website located at www.sec.gov. Electronic copies of the final prospectus supplement and the accompanying prospectus may be obtained, when available, by contacting Aegis Capital Corp., Attention: Syndicate Department, 1345 Avenue of the Americas, 27th floor, New York, NY 10105, by email at syndicate@aegiscap.com, or by telephone at +1 (212) 813-1010.
Interested parties should read in their entirety the prospectus supplement and the accompanying prospectus and the other documents that the Company has filed with the SEC that are incorporated by reference in such prospectus supplement and the accompanying prospectus, which provide more information about the Company and such offering.
This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About DSS, Inc.
DSS, Inc. (NYSE American: DSS) is a multinational company operating across multiple business lines including product packaging, biotechnology, commercial lending, and securities and investment management. The Company operates a business model based on developing high-growth subsidiaries and unlocking value through strategic IPOs and public listings. For more information, visit www.dssworld.com.
Forward-Looking Statements
The foregoing material may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. Forward-looking statements include all statements that do not relate solely to historical or current facts, including without limitation statements regarding the Company’s product development and business prospects, and can be identified by the use of words such as “may,” “will,” “expect,” “project,” “estimate,” “anticipate,” “plan,” “believe,” “potential,” “should,” “continue” or the negative versions of those words or other comparable words. Forward-looking statements are not guarantees of future actions or performance. These forward-looking statements are based on information currently available to the Company and its current plans or expectations and are subject to a number of risks and uncertainties that could significantly affect current plans. Should one or more of these risks or uncertainties materialize, or the underlying assumptions prove incorrect, actual results may differ significantly from those anticipated, believed, estimated, expected, intended, or planned. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, the Company cannot guarantee future results, performance, or achievements. Except as required by applicable law, including the security laws of the United States, the Company does not intend to update any of the forward-looking statements to conform these statements to actual results.
For investor and media inquiries or additional information, please contact:
Investor Contact:
DSS, Inc.
Investor Relations
ir@dssworld.com
+1 (585) 565-2422
